Leonard A. Potter
Co-Founder @ Vida Ventures
New York, United States
Leonard A. Potter is a Series A investor at Vida Ventures in New York focused on Biotechnology and Health Diagnostics. Mr. Potter has served as a member of our Board of Directors since 2011. Mr. Potter is currently the President and Chief Investment Officer of Wildcat Capital Management, LLC, a registered investment advisor. From August 2009 through August 2011, Mr. Potter served as the Chief Investment Officer of Salt Creek Hospitality, a private acquirer andowner of hospitality related assets. From December 2002 through July 2009, Mr. Potter was a Managing Director — Soros Private Equity at Soros Fund Management LLC (“SFM”) where, from May 2005 through July 2009, Mr. Potter served as co-head of the Private Equity group and a member of the Private Equity Investment Committee. From September 1998 until joining SFM in 2002, Mr. Potter was a Managing Director of Alpine Consolidated LLC, a private merchant bank, and from April 1996 through September 1998, Mr. Potter founded and served as a Managing Director of Capstone Partners LLC, a private merchant bank. Prior to founding Capstone Partners, Mr. Potter was an attorney specializing in mergers, acquisitions and corporate finance at Morgan, Lewis & Bockius and Willkie Farr & Gallagher. Mr. Potter is currently a member of the board of directors of Solar Senior Capital, Ltd., Solar Capital Ltd. and GSV Capital, each a business development company, and Crumbs Bake Shop, Inc. (“CRMB”), and has previously served as a board member of several other public companies.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Leonard A. Potter invests in
Stages Leonard A. Potter invests in
Countries Leonard A. Potter invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (67%)
- Health Diagnostics 2 (67%)
- Health Care 1 (33%)
- Neuroscience 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Series C 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease. The company has developed a novel retinal imaging technology, which is currently being utilized in a number of clinical trialsglobally.With access to unique datasets, we provide data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases. | $11.2M / Series C / May 02, 2018 | ||
| Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing andadvanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. | $411.8M / Series A / Apr 19, 2018 | ||
| NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease. The company has developed a novel retinal imaging technology, which is currently being utilized in a number of clinical trialsglobally.With access to unique datasets, we provide data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases. | $10M / Series B / Jun 29, 2016 |
Co-Investors
About Vida Ventures
Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists,physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine .
Vida Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fred Cohen
Co-Founder & Sr. Managing Director
|
|||
Helen Kim
Senior Managing Director
|
|||
Mark Springel
Associate
|
|||
Arie Belldegrun
Co-Founder & Senior Managing Director; Founding Partner
|
|||
Arjun Goyal
Co-Founder and Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Leonard A. Potter invest in?
Leonard A. Potter invests primarily in Biotechnology, Health Diagnostics and Health Care startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Leonard A. Potter?
Public channels for Leonard A. Potter include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Leonard A. Potter last invest?
The most recent investment recorded for Leonard A. Potter closed in May 2018. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
